Compare Stocks: AVTE, NBTX, STOK, and ABSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$11.07 +3.0%	$9.02	$2.24 ▼ $12.06	$1.84B	2.27	3.85 million shs	3.38 million shs
AVTE Aerovate Therapeutics	$14.12 +2.5%	$19.58	$89.95 ▼ $99.05	$409.27M	0.95	53,591 shs	1.11 million shs
NBTX Nanobiotix	$25.75 -7.7%	$37.81	$14.78 ▼ $57.14	$1.30B	0.79	132,230 shs	255,765 shs
STOK Stoke Therapeutics	$25.62 -1.5%	$29.91	$20.32 ▼ $40.22	$1.68B	1.26	921,647 shs	581,420 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+2.98%	+13.66%	+25.80%	-4.73%	+253.67%
AVTE Aerovate Therapeutics	-1.99%	-6.52%	-34.49%	-35.98%	+59.56%
NBTX Nanobiotix	-7.71%	-22.70%	-38.20%	-32.94%	+37.41%
STOK Stoke Therapeutics	-1.50%	+3.31%	-16.00%	-21.65%	+8.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$11.07 +3.0%	$9.02	$2.24 ▼ $12.06	$1.84B	2.27	3.85 million shs	3.38 million shs
AVTE Aerovate Therapeutics	$14.12 +2.5%	$19.58	$89.95 ▼ $99.05	$409.27M	0.95	53,591 shs	1.11 million shs
NBTX Nanobiotix	$25.75 -7.7%	$37.81	$14.78 ▼ $57.14	$1.30B	0.79	132,230 shs	255,765 shs
STOK Stoke Therapeutics	$25.62 -1.5%	$29.91	$20.32 ▼ $40.22	$1.68B	1.26	921,647 shs	581,420 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+2.98%	+13.66%	+25.80%	-4.73%	+253.67%
AVTE Aerovate Therapeutics	-1.99%	-6.52%	-34.49%	-35.98%	+59.56%
NBTX Nanobiotix	-7.71%	-22.70%	-38.20%	-32.94%	+37.41%
STOK Stoke Therapeutics	-1.50%	+3.31%	-16.00%	-21.65%	+8.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.71	23.89% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
NBTX Nanobiotix	2.50	Moderate Buy	$46.67	81.23% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	72.72% Upside

Current Analyst Ratings Breakdown

Latest AVTE, NBTX, STOK, and ABSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	ABSI Absci	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/15/2026	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$64.00
9/10/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$15.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
8/21/2026	STOK Stoke Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$40.00
8/12/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	678.47	N/A	N/A	$1.26 per share	8.79
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
NBTX Nanobiotix	$8.36M	155.95	N/A	N/A	($1.97) per share	-13.07
STOK Stoke Therapeutics	$27.59M	59.92	N/A	N/A	$6.17 per share	4.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
NBTX Nanobiotix	-$27.11M	N/A	N/A	160.94	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest AVTE, NBTX, STOK, and ABSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
AVTE Aerovate Therapeutics	N/A	8.78	8.78
NBTX Nanobiotix	N/A	1.44	N/A
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
AVTE Aerovate Therapeutics	N/A
NBTX Nanobiotix	38.81%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
AVTE Aerovate Therapeutics	24.90%
NBTX Nanobiotix	3.45%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
NBTX Nanobiotix	97	50.62 million	48.87 million	Not Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

AVTE, NBTX, STOK, and ABSI Headlines

Recent News About These Companies

Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock

October 3 at 5:52 AM | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock

October 3 at 5:52 AM | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock

October 3 at 5:52 AM | insidertrades.com

Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

October 2 at 7:07 PM | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock

October 2 at 7:07 PM | marketbeat.com

Financial Contrast: Stoke Therapeutics (NASDAQ:STOK) & Invivyd (NASDAQ:IVVD)

September 27, 2026 | americanbankingnews.com

Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 27, 2026 | marketbeat.com

Stoke Therapeutics, Inc. Announces Board Changes

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

September 23, 2026 | businesswire.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 9% - What's Next?

September 23, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts

September 23, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | marketbeat.com

Stoke Therapeutics stock holds gains after recent data update

September 19, 2026 | ad-hoc-news.deA

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - September 16, 2026

September 17, 2026 | biospace.comB

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 16, 2026 | businesswire.com

Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 8, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares of Stock

September 4, 2026 | insidertrades.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...

September 3, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, NBTX, STOK, and ABSI Company Descriptions

Absci NASDAQ:ABSI

$11.07 +0.32 (+2.98%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$11.09 +0.02 (+0.18%)

As of 10/2/2026 07:57 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Aerovate Therapeutics NASDAQ:AVTE

$14.12 +0.35 (+2.54%)

As of 10/2/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Nanobiotix NASDAQ:NBTX

$25.75 -2.15 (-7.71%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.77 +0.02 (+0.08%)

As of 10/2/2026 07:32 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Stoke Therapeutics NASDAQ:STOK

$25.62 -0.39 (-1.50%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.62 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, NBTX, STOK, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, NBTX, STOK, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, NBTX, STOK, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, NBTX, STOK, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Aerovate Therapeutics NASDAQ:AVTE

Nanobiotix NASDAQ:NBTX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, NBTX, STOK, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, NBTX, STOK, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, NBTX, STOK, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, NBTX, STOK, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Aerovate Therapeutics NASDAQ:AVTE

Nanobiotix NASDAQ:NBTX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools